Ziresovir

DB15145InvestigationalSmall molecule

Ziresovir is under investigation in clinical trial NCT03699202 (Anti-RSV Study in Chinese Patients (ASCENT)).

Mechanism: Pharmacologically active on Fusion glycoprotein F0
Curator reviewed
Formula / weight: C₂₂H₂₅N₅O₃S · 439.53 g/mol (avg)
Code names: AK0529

Resolves to

Compound

Structure

InChIKeyGAAICKUTDBZCMT-UHFFFAOYSA-NSMILESCC1=CC2=C(NCC3(N)COC3)N=C(N=C2C=C1)N1CCS(=O)(=O)C2=CC=CC=C2C1

Targets

What you can answer from here — as of July 08, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

10Clinical trialsPhase, status and sponsor resolved per trial

6+ReferencesStructured and connected to the statements they support

Which drugs share a target with Ziresovir, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.